Blog

• 
• 
• 
• 

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.

As part of the initial research project, Tempus will use its Tempus O platform to collect and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations.

Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, a global pharmaceutical company based in Denmark, to develop a novel approach for treating schizophrenia.

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) that act on a receptor in the brain that has been implicated in schizophrenia.

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Their findings, published recently in the journal Neuron, focus on M4, a subtype of the muscarinic acetylcholine family of nerve cell (neuron) receptors activated by binding the neurotransmitter acetylcholine.

One Vanderbilt Technology earned patent protection

Four new Vanderbilt technologies earn patent protection in November

9,826,904    System and method for detecting tissue surface properties

A team of scientists from Vanderbilt University, led by Professor John Wikswo, have won an R&D 100 Award for their MultiWell MicroFormulator device. The MultiWell MicroFormulator, developed at Vanderbilt and being commercialized by CN Bio Innovations, provides customized realtime formulation, delivery, and removal of cell culture media to each well of a 96-well plate for drug discovery, toxicology research, and personalized medicine.

Seven new Vanderbilt technologies earn patent protection in October.

9,803,758       Spool and body architectures for three-position directional control valves

Alzheimer's Disease Innovations

CTTC can help connect those interested in launch technology-based new ventures to programs provided by the state’s Launch TN – whose mission is to make Tennessee the best place in the Southeast to start and grow a business.  Launch TN’s resources for entrepreneurial researchers include a mentorship program, microgrants for SBIR/STTR grant-writing support, and an SBIR/STTR matching fund for young companies.  More information is available in the Launch TN Flyer or on LaunchTN.org.